Doxorubicin-induced oxygen free radical formation in sensitive and doxorubicin-resistant variants of rat glioblastoma cell lines  by Benchekroun, M.Nabil et al.
Volume 326, number 1,2,3 FEBS LETTERS July 1993 
Benchekroun, M.N., Sinha, B.K. and Robert, J., Doxorubicin-induced oxygen free radical formation in sensitive and 
doxorubicin-resistant variants of rat glioblastoma cell lines, FEBS Letters, 322 (1993) 295-298. 
As the result of a faulty conversion during the editing of this paper some of the '/~' symbols were replaced by an 'm'. 
The errors occurred in sections 2.1. and 2.2., and in the legends to Figs. 1 and 2. 
The complete corrected article has been reprinted on the next four pages. 
The publishers apologise for any inconvenience these errors may have caused. 
301 
Volume 322, number 3, 295-298 FEBS 12456 May 1993 
© 1993 Federation of European Biochemical Societies 00145793193l$6.00 
Doxorubicin-induced oxygen free radical formation in sensitive and 
doxorubicin-resistant variants of rat glioblastoma cell lines 
M. Nabi l  Benchekroun a'b, B i randra K. Sinha b and Jacques Rober t  ax 
aDOpartement de Biochimie MOdicale et Biologie molOculaire, UniversitO de Bordeaux II, 146 rue LOo Saignat, 33076 Bordeaux-COdex, 
France, bBiochemical & Molecular Pharmacology Section, Clinical Pharmacology Branch, National Cancer Institute, National 
Institutes of Health, Bethesda, MD 20892, USA and CLaboratoire de Biochimie et Pharmacologie, Fondation BergoniO, 180 rue de 
Saint GenOs, 33076 Bordeaux-COdex, France 
Received 17 March 1993; revised version received 26 March 1993 
We have studied the formation of hydroxyl radical (OH') induced by doxorubicin in a series of doxorubicin- or vincristine-selected variants of C6 
rat glioblastoma cells in culture by electron-spin resonance spectroscopy using 5,5'-dimethyl-l-pyrroline-l-oxide as a spin trap. Wild-type cells, 
sensitive to doxorubicin, exhibited in the presence of this drug a concentration-dependent OH" formation which could be inhibited by preincubation 
with superoxide dismutase, catalase or an antibody against cytochrome P450-reductase. In highly doxorubicin-resistant cells, OH" formation was 
reduced to about 20% of the level obtained in sensitive cells. In cells presenting a very low level of resistance to doxorubicin or in cells selected 
with vincristine, both presenting a pure multidrug-resistant phenotype, OH" formation was identical to that obtained in sensitive cells. In cells of 
intermediate r sistance or in revertant cells, intermediate l vels of OH" formation were obtained. Protection against OH" formation and action can 
be identified at the levels of superoxide dismutase and glutathione peroxidase activities, which are both enhanced in the resistant cells. 
Anthracycline; Electron spin resonance spectroscopy; Free radical; Anticancer drug; Redox activation; Lipid peroxidation 
1. INTRODUCTION 
The exact role of doxorubicin-induced free radical 
formation in the cytotoxicity of this anticancer drug has 
been the matter of important controversy [1]. It is now 
generally accepted that the nuclear enzyme DNA-topo- 
isomerase II is one of the primary targets of doxorubi- 
cin, which induces the formation of cleavable complexes 
and transforms this enzyme into an endogenous poison. 
This does not exclude, however, other possible toxic 
roles of doxorubicin at the cellular level. As several 
quinone compounds, doxorubicin can induce free radi- 
cal formation through one-electron activation by 
NADPH-cytochrome P450 reductase [2]. The resulting 
oxygen free radicals, O2 -° and OH',  which are succes- 
sively formed, can damage cell components at the level 
where they occur. This toxicity is probably not respon- 
sible for doxorubicin-induced tumor cell kill in the in 
vitro models used for cytotoxicity evaluation ; it can be 
hypothesized, however, that in cells lacking topoisom- 
erase II activity as a primary hypersensitive target, the 
damages caused by oxygen free radicals can explain cell 
death. This could be for instance the case of cells resis- 
tant to doxorubicin [3] especially since they have been 
shown to develop no DNA breaks at cytotoxic expo- 
sures [4]. We have recently shown that it was possible 
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to evaluate the degree of doxorubicin-induced lipid per- 
oxidation in tumor cells [5], and that it was related to 
the glutathione peroxidase activity of the cells [6]. We 
wanted then to know if this was related to the formation 
of oxygen free radicals; we have therefore valuated the 
formation of hydroxyl radical upon doxorubicin expo- 
sure in cells sensitive and resistant o this drug, espe- 
cially in cells having developed mechanisms of resis- 
tance other than P-glycoprotein overexpression, and 
displaying an intracellular tolerance to the drug [7]. We 
show in this paper that doxorubicin was able to induce 
hydroxyl radical formation in C6 rat glioblastoma cells, 
and that this production was decreased especially in the 
cells displaying a non-MDR resistance to this drug as 
an additional mechanism to classical MDR. We also 
show that there is a correlation between the decrease of 
doxorubicin-induced free radical formation and the su- 
peroxide dismutase and glutathione peroxidase activi- 
ties of the cell lines. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
C6 rat glioblastoma cells [8] were grown with stepwise increasing 
amounts of doxorubicin so as to obtain a series of lines of increasing 
resistance. These lines have been already characterized in previous 
papers [7,9]. Briefly, C6 0.001 currently grow with 0.001 ~tg doxorubi- 
cin per ml medium and are 5-fold resistant to this drug through a pure 
MDR mechanism; C6 0.1 cells grow with 0.1 ¢tg/ml doxorubicin, are 
50-fold resistant o this drug, and part of this resistance cannot be 
explained only by P-glycoprotein overexpression; C6 0.5 cells grow 
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with 0.5 ktg/ml doxorubicin, are 400-fold resistant, but overexpress 
P-glycoprotein to the same level as C6 0.1 cells, indicating that most 
of the resistance acquired by this line as compared to the C6 0.1 one 
is unrelated to P-glycoprotein expression. A revertant line, C6 Rev, 
was obtained from C6 0.5 cells by one year culture in drug-free me- 
dium, and presents a degree of resistance of 2-fold as compared to C6 
sensitive cells. To this panel of doxorubicin-selected lines was added 
a vincristine-selected line, C6 IV, growing with 1 ¢tg/ml vincristine, 
and presenting both a high degree of resistance to vincristine (400- 
fold) and to doxorubicin (100-fold). 
An important feature, unrelated to classical multidrug resistance, 
is the possible intracellular accumulation of doxorubicin in the most 
resistant cells selected with doxorubicin, without concomitant cyto- 
toxicity. This 'intracellular tolerance' can be quantified as 'intracellu- 
lar ICs0', i.e. the accumulation of doxorubicin accompanying 50% 
growth inhibition of the cell line. This intracellular ICs0 is identical in 
C6 sensitive, C6 0.001, C6 Rev and C6 1V cells; it is in contrast 4-fold 
higher in C6 0.1 cells and 17-fold higher in C6 0.5 cells than in sensitive 
cells (see [7]). 
Cells were routinely cultivated in DMEM supplemented with 10% 
fetal calf serum, in a 5% COz atmosphere at 37°C. They were repli- 
cated each week and the culture medium was changed 2 times between 
passages. 
2.2. Estimation of free radical formation 
We have used electron spin resonance (ESR) spectroscopy with 
5,5'-dimethyl-l-pyrroline-l-oxide (DMPO) as a spin trap, according 
to Kalyanaraman [10], as already described [3]. The formation of the 
complex DMPO-OH ° is detected by this technique and reveals the 
presence of hydroxyl radicals. The cells were harvested after trypsini- 
zation and washed twice with ice-cold phosphate-buffered saline with- 
out calcium or magnesium. They were used at a density of 5 x 106/ml 
and the reaction medium (total volume: 0.4 ml) contained DMPO (50 
mM), NADPH (1 mM), and doxorubicin (50-300 ,uM) in phosphate- 
buffered saline (50 mM, pH 7.4). A Varian E-109 spectrometer oper- 
ating at 9.5 GHz with a field modulation of 100 kHz was used for these 
studies. The DMPO-OH ° spectrum consists of a quartet (1 : 2 : 2 : 1) 
with hyperfine splitting constants of 14.9 G [11]. Experiments were 
performed either on intact cells or on cells sonicated on ice for 3 x 15 
s at 50 W. Reactions were also done in the presence of 40 pl of 10% 
ethanol, which is a known scavenger of OH', and forms DMPO- 
carbon centered radicals. Preincubations (30 min on ice) with 100 
pg/ml superoxide dismutase (Sigma), 100 pg/ml catalase (Sigma), or 
with an antibody against rat cytochrome P450-reductase (a generous 
gift from Dr. Krishna, National Institutes of Health, Bethesda) were 
also performed. Similar preincubations in the absence of enzymes or 
antibodies had no effect on the ESR spectra recorded. 
2.3. Evaluation of glutathione and of detoxifying enzymes 
Reduced glutathione was assayed in the cells by the spectrophotom- 
etric technique of Brehe and Butch [12] using glutathione reductase 
(Sigma). Glutathione peroxidase was estimated by the technique of 
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Fig. 1. ESR spectra obtained from C6 sensitive cells (5 x 106 cells/ml) in the presence of DMPO (50 mM) and NADPH (1 mM) in phosphate-buffered 
saline (50 raM, pH 7.4) (final volume: 0.4 ml). The hyperfine coupling constants for DMPO-OH were: a N = a H = 14.9 G. The ESR settings were: 
center field = 3364 G; microwave power = 20.0 G; modulation amplitude = 2.0 G; receiver gain = 8 x 104. (A) Control without doxorubicin; (B) 
doxorubicin: 50 ¢tM; (C) doxorubicin: 100/.tM; (D) doxorubicin: 200 ,uM; (E) doxorubicin: 300 ,uM; (F) doxorubicin: 200 ,uM; the reaction was 
done in the presence of 40 pl of 10% ethanol; (G) doxorubicin: 200 pM ; the cells were preincubated with superoxide dismutase (100 pg/ml for 
30 min on ice; (H) doxorubicin: 200 mM; the cells were preincubated with catalase (100 pg/ml) for 30 min on ice; (I) doxorubicin: 200 mM; antibody 
to cytochrome P450-reductase was added to the lysed cell preparation. 
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Lawrence and Burk [13] using the supernatant a 25,000 x g of a cell 
sonicate. The assay was performed in the presence of reduced glutathi- 
one (1 mM) and a glutathione regenerating system. The peroxide 
source was either cumene hydroperoxide (1.5 mM) for total glutathi- 
one peroxidase activity, or hydrogen peroxide (0.25 mM) for selenium- 
dependent glutathione peroxidase activity. Bovine erythrocyte gluta- 
thione peroxidase was used as a standard for calibration of the assay. 
Superoxide dismutase was evaluated by the technique of Marklund 
and Marklund [14] on the same cell preparation as the one used for 
glutathione peroxidase valuation. Superoxide dismutase activity is 
expressed in arbitrary International Units (IU), l IU being able to 
inhibit by 50% the autooxidation f pyrogallol. 
Catalase was evaluated according to Beers and Sizer [15] on the 
same cell preparation. 
3. RESULTS 
Fig. 1 presents a series of  ESR spectra obtained from 
C6 sensitive cells. No  signal was present in the absence 
of  either doxorubic in or the cell preparat ion.  There was 
a concentrat ion-dependent increase of  the DMPO ad- 
duct format ion up to 200 mM doxorubicin.  Incubat ion 
with ethanol strongly decreased the signal, indicating 
that the OH" formed from doxorubic in were free hy- 
droxyl radicals t rapped by DMPO.  The addit ion of  su- 
peroxide dismutase or of  catalase provided respectively 
a 70% and a 30% inhibit ion of  adduct formation,  indi- 
cating that 02-" and H20 2 were important  intermediates 
in the product ion of  OH' .  Incubat ion of  lyzed cells with 
an ant ibody against cytochrome P450-reductase com- 
pletely abol ished the ESR signal. Fig. 2 presents ESR 
spectra obtained from the C6 doxorubic in resistant var- 
iants incubated with 200 mM doxorubicin.  C6 0.001 
and C6 1V cells were able to form the same amount  of  
DMPO-OH adduct as C6 sensitive cells, whereas C6 
Rev, C6 0.1 and C6 0.5 cells respectively formed 1.5, 3.4 
and 4.5 less adducts than C6 sensitive cells. This reduc- 
tion was only part ly due to the reduced doxorubic in 
accumulat ion occurring in mult idrug resistant cells, 
since after sonication, lyzed C6 0.5 cells still presented 
a 3-fold reduction of  DMPO adduct format ion as com- 
pared to C6 sensitive cells. As in sensitive cells, preincu- 
bat ion of  the C6 1V or C6 Rev cells with superoxide 
dismutase or catalase strongly decreased the ESR sig- 
nal. Table I presents the levels of  reduced glutathione 
as well as the activities of  glutathione peroxidase, cata- 
lase and superoxide dismutase measured in the various 
cell lines. It appears that C6 0.1 and C6 0.5 cells have 
34- fo ld  higher levels of  both selenium-dependent and 
non-selenium-dependent enzyme activities as compared 
to sensitive and C6 0.001 cells. It also appeared in the 
same cell lines an increase of  superoxide dismutase ac- 
tivity, whereas basic glutathione levels as well as cata- 
lase activity remained unchanged in the cell lines stud- 
ied. 
4. D ISCUSSION 
Sinha et al. [3] were the first to show the differential 
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Fig. 2. ESR spectra obtained from C6 cell resistant variants (5 × l0  6 
cells/ml) in the presence of DMPO (50 mM), NADPH (1 mM) and 
doxorubicin (200/.tM). (A) C6 0.001 cells; (B) C6 0.1 cells; (C) C6 0.5 
cells; (D) lyzed C6 0.5 cells; (E) C6 Rev cells; (F) C6 Rev cells prein- 
cubated with superoxide dismutase (100/.tg/ml) for 30 min on ice; (G) 
C6 1V cells; (H) C6 1V cells preincubated with superoxide dismutase 
(100/lg/ml) for 30 min on ice; (I) C6 1V cells preincubated with 
catalase (100 ,ug/ml) for 30 min on ice. 
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Table I 
Glutathione l vels and free-radical scavenging enzyme activities in the cell lines studied 
Glutathione Glutathione peroxidase Catalase Superoxide 
nmol/mg protein/min ¢tmol/mg dismutase 
protein/min UI/mg 
Se-dependent non Se-dependent protein/min 
C6 70.9 _+ 8.1 23.5 _+ 3.6 57.9 + 7.8 9.30 + 2.56 4.26 _+ 0.61 
C6 0.001 68.0 _+ 9.0 30.7 _+ 4.9 65.2 _+ 6.5 8.41 + 1.75 3.80 + 0.45 
C6 0.t 76.2 + 9.6 91.2 + 12.0 205 _+ 43 8.00 + 2.00 7.10 + 1.00 
C6 0.5 85.5 + 14.2 153 _+ 26 319 + 61 7.87 + 2.10 9.72 + 1.83 
C6 Rev 52.0 + 2.9 50.3 + 14.4 133 _+ 24 nd 6.24 _+ 0.77 
formation of hydroxyl radicals by doxorubicin in sensi- 
tive and resistant umor MCF-7 cells in culture. It was 
not clear at that time if this reduction was or was not 
part of the multidrug resistance phenotype. Other au- 
thors have then strongly doubted the role of hydroxyl 
radicals in the cytotoxic effect of doxorubicin [1]. It 
appears from our work that the early development of 
doxorubicin resistance is not accompanied by a reduc- 
tion of free radical production; the C6 0.001 and the C6 
1V lines appear as pure MDR lines, their resistance to 
doxorubicin being only due to the overexpression of 
P-glycoprotein. In contrast, the C6 0.5 line, which can 
tolerate high intracellular amounts of drug, presents 
several features not directly associated with classical 
MDR: it is able to strongly decrease free radical forma- 
tion, as shown in this paper; it is also able to avoid the 
doxorubicin-induced lipid peroxidation as shown ear- 
lier [6]. The C6 0.1 and C6 Rev lines behave somewhat 
like the C6 0.5 line, but the inhibition of DMPO adduct 
formation occurs to a much lesser extent. 
It can be hypothesized that in cell lines selected with 
doxorubicin to a high level of resistance, like MCF-7 
doxR cells studied by Sinha et al. [3] or C6 0.5 cells 
studied here, mechanisms other than P-glycoprotein- 
mediated rug efflux could occur and participate to the 
phenotype of resistance; these mechanisms might pro- 
tect the various intracellular targets of doxorubicin. At 
the level of the endoplasmic reticulum, where high levels 
of doxorubicin could cause lipid peroxidation via free 
radical formation, detoxification procedures would be 
necessary, explaining then the tolerance that these 
highly resistant cells develop as a mechanism additional 
to MDR. In contrast, in the line selected with vin- 
cristine, an anticancer drug recognized by P-glycopro- 
tein but not able to form free radicals upon activation, 
as well as in the first steps of selection of resistant cells 
by doxorubicin, these systems of detoxification would 
not develop, since no decrease in doxorubicin-induced 
DMPO adduct formation occured. 
Two systems at least can be involved in our cell lines 
for the protection against free radical production and 
effects: the increase of superoxide dismutase activity, 
which can detoxify O2 °-, and the increase of glutathione 
peroxidase, which can detoxify hydrogen and organic 
peroxides formed from oxygen free radicals. We have 
already shown that there is a significant inverse rela- 
tionship between glutathione peroxidase activity and 
doxorubicin-induced lipid peroxidation in cell lines of 
different origin [6]. We show here that the decrease in 
doxorubicin-induced lipid peroxidation observed in the 
resistant cells can also be attributed to a diminished 
formation of hydroxyl radical, which might be ex- 
plained at least in part by an overactivity of superoxide 
dismutase in the resistant cells. This may contribute to 
the non-MDR mechanism of resistance of the cells stud- 
ied. 
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